Bristol Myers Squibb announces positive topline results from two studies
Bristol Myers Squibb, a member of Bio Nebraska, announced that TRANSCEND FL and TRANSCEND NHL 001 studies of Breyanzi (lisocabtagene maraleucel) in relapsed or refractory follicular lymphoma and mantle cell lymphoma meet primary endpoint of overall response rate. Read more